Leukemia Disease State Predictor

60-minute live analyst briefing focused on the Leukemia Therapeutics Market, helping healthcare and life sciences leaders optimize AWS-cloud strategies for oncology analytics, AI-driven forecasting, clinical data scaling, and precision medicine planning.

The global Leukemia Therapeutics Market is expected to reach $29 billion by 2030, exhibiting a CAGR of 9% from 2024 to 2030. The substantial growth is attributed to the emergence of innovative treatments like bone marrow transplants and menine inhibition in cancer therapeutics. These advancements not only enhance patient outcomes but also hold the potential to positively impact the healthcare sector, driving further market expansion.

Beat AML 1.0 is a collaborative research program involving 11 academic medical centers who worked collectively to better understand drugs and drug combinations that should be prioritized for further development within clinical and/or molecular subsets of acute myeloid leukemia (AML) patients. Beat AML 1.0 provides the largest-to-date dataset on primary acute myeloid leukemia samples offering genomic, clinical, and drug response. This dataset contains open Clinical Supplement and RNA-Seq Gene Expression Quantification data. This dataset also contains controlled Whole Exome Sequencing (WXS) and RNA-Seq Aligned Reads, WXS Annotated Somatic Mutation, WXS Raw Somatic Mutation, and RNA-Seq Splice Junction Quantification

The OHSU-CNL study offers the whole exome and RNA-sequencing on a cohort of 100 cases with rare hematologic malignancies such as Chronic neutrophilic leukemia (CNL), atypical chronic myeloid leukemia (aCML), and unclassified myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN-U). This dataset contains open RNA-Seq Gene Expression Quantification data.